Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
BACKGROUND: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) persist better to 3½ years of age after a 12-month booster dose of a combination Hib-MenC glycoconjugate vaccine (Hib-MenC-TT) in children primed in infancy with Hib-MenC-TT and diphther...
主要な著者: | Khatami, A, Snape, MD, Wysocki, J, John, T, Westcar, S, Mesaros, N, Peddiraju, K, Boutriau, D, Yu, L, Pollard, A |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2012
|
類似資料
-
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
著者:: Pace, D, 等
出版事項: (2008) -
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
著者:: Pace, D, 等
出版事項: (2008) -
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
著者:: Khatami, A, 等
出版事項: (2013) -
Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
著者:: Khatami, A, 等
出版事項: (2011) -
Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
著者:: Marzia Monica Giuliani, 等
出版事項: (2021-05-01)